1. Home
  2. IFRX vs SY Comparison

IFRX vs SY Comparison

Compare IFRX & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • SY
  • Stock Information
  • Founded
  • IFRX 2007
  • SY 2013
  • Country
  • IFRX Germany
  • SY China
  • Employees
  • IFRX N/A
  • SY N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • SY EDP Services
  • Sector
  • IFRX Health Care
  • SY Technology
  • Exchange
  • IFRX Nasdaq
  • SY Nasdaq
  • Market Cap
  • IFRX 117.8M
  • SY 98.6M
  • IPO Year
  • IFRX 2017
  • SY 2019
  • Fundamental
  • Price
  • IFRX $1.05
  • SY $0.87
  • Analyst Decision
  • IFRX Strong Buy
  • SY Hold
  • Analyst Count
  • IFRX 2
  • SY 1
  • Target Price
  • IFRX $9.00
  • SY $0.80
  • AVG Volume (30 Days)
  • IFRX 356.5K
  • SY 368.3K
  • Earning Date
  • IFRX 03-20-2025
  • SY 03-28-2025
  • Dividend Yield
  • IFRX N/A
  • SY 6.67%
  • EPS Growth
  • IFRX N/A
  • SY N/A
  • EPS
  • IFRX N/A
  • SY N/A
  • Revenue
  • IFRX $171,642.00
  • SY $200,942,308.00
  • Revenue This Year
  • IFRX $381.73
  • SY $2.13
  • Revenue Next Year
  • IFRX $2,277.23
  • SY $4.64
  • P/E Ratio
  • IFRX N/A
  • SY N/A
  • Revenue Growth
  • IFRX 162.79
  • SY N/A
  • 52 Week Low
  • IFRX $1.01
  • SY $0.66
  • 52 Week High
  • IFRX $2.82
  • SY $1.42
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 31.57
  • SY 43.94
  • Support Level
  • IFRX $1.16
  • SY $0.88
  • Resistance Level
  • IFRX $1.30
  • SY $0.98
  • Average True Range (ATR)
  • IFRX 0.12
  • SY 0.08
  • MACD
  • IFRX 0.02
  • SY -0.01
  • Stochastic Oscillator
  • IFRX 9.76
  • SY 23.39

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenues from information services fees and reservation services fees from medical aesthetic service providers.

Share on Social Networks: